An integrated understanding of the metabolic benefits of a novel double-targeted genetically engineered probiotic expressing aldafermin intervention with dietary change on NAFLD

Saved in:
Bibliographic Details
Published inAtherosclerosis Vol. 379; p. S32
Main Authors Babu, A.F., Iannone, V., Lok, J., Gomez-Gallego, C., D'Auria, G., Vazquez-Uribe, R., Pihlajamaki, J., Sommer, M., Hanhineva, K., El-Nezami, H., Kohlemainen, M.
Format Journal Article
LanguageEnglish
Published 01.08.2023
Online AccessGet full text

Cover

More Information
ISSN:0021-9150
DOI:10.1016/j.atherosclerosis.2023.06.772